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Abstract
Objective. The aim of this study was to evaluate the role of rituximab (RTX) in modulating the expression
of the IL-17/IL-23 pathway in the salivary glands (SGs) of patients with primary SS (pSS).
Methods. Consecutive SG biopsies were obtained from 15 patients with pSS before and after 1 year of
RTX therapy. The SG expression of IL-17, IL-23p19 and p-STAT3 was evaluated by immunohistochemistry
at baseline and after RTX therapy. The role of mast cells in pSS patients in modulating the Th17 response
and the immunologic effect of RTX on mast cells were also studied in in vitro experiments.
Results. IL-17 was overexpressed in the SGs of patients with pSS mainly by infiltrating T cells and mast
cells. After RTX therapy, the SG expression of IL-17, but not of IL-23p19 and p-STAT3, was significantly
reduced and was accompanied by the depletion of tissue mast cells. In in vitro experiments with heter-
ologous peripheral lymphocytes RTX significantly induced the apoptosis of isolated mast cells. Finally,
mast cells isolated from peripheral blood mononuclear cells of pSS patients in vitro significantly increased
Th17 lymphocytes.
Conclusion. RTX acts on pSS patients by globally reducing the expression of IL-17 and specifically
inducing a pronounced apoptotic depletion of mast cells.
Key words: rituximab, mast cells, IL-17, IL-23, p-STAT3, primary Sjo¨gren’s syndrome, T lymphocytes, mast
cells.
Introduction
Primary SS (pSS) is a chronic autoimmune inflammatory
disorder in which salivary gland (SG) inflammation occurs
in the presence of altered adaptive and innate immune
responses [1] seen as altered serum and tissue cytokine
expression of, for example, the IL-23p19/IL-17 pathway
[27]. The neutralization of IL-23p19 and/or IL-17 thus ap-
pears to be a promising therapeutic approach in pSS.
Despite the fact that IL-17 inhibition may directly inter-
fere with the onset of SS-like disease in mice [8], clin-
ical studies involving patients with pSS are currently
missing.
Rituximab (RTX), an mAb to CD20, has been used and
proved to be effective in reducing symptoms and in ame-
liorating the degree of tissue inflammation in pSS patients
[911]. Beyond its role in depleting B cells, RTX seems to
be able to modulate the T cell responses in autoimmune
diseases [12, 13].
The aim of the present work was to clarify whether RTX
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University Hospitals (Italy). Disease activity was assessed
using the visual analogue scales (VASs) for global dis-
ease activity. All the patients had active disease with
values >50 mm on more than two of four 100-mm
VASs (global disease activity including extraglandular
manifestations, pain, sicca syndrome and fatigue)
during the last 3 months. Additional inclusion criteria
were positivity for either anti-SSA and/or anti-SSB auto-
antibodies. Ten patients with subjective complaints of
dry mouth or eyes who did not meet the
AmericanEuropean Consensus Group criteria for pSS
were considered as the control group (nSS). Baseline
characteristics of patients and controls are summarized
in Table 1. All the pSS patients were treated with two
cycles of i.v. infusions of 1000 mg RTX (Roche, Woerden,
The Netherlands) on days 1 and 15 (at time 0 and then
after 6 months). After 48 weeks the patients underwent
another SG biopsy. The study was approved by the
Ethical Committee of the University of Palermo.
Patients signed informed consent for the collection and
storage of biological material.
Labial SG biopsy
Labial SG biopsies were obtained and placed into formalin
fixative and RNA. Standard 5-mm thick paraffin sections
were stained with haematoxylin and eosin (H&E).
Histological evaluation of SGs for the presence of lympho-
cytic infiltrates and/or foci was performed according to
the classification of Chisholm and Mason. A focus was
defined as an aggregate of 550 lymphocytes. The focus
score was reported as the number of foci per 4 mm2 of
tissue, up to a maximum of 12 foci. All pSS patients pre-
sented a biopsy focus score >1, whereas the control
group had a focus score <1.
Immunohistochemistry
Tissue samples were immediately fixed with 4% formal-
dehyde and embedded in paraffin. Immunohistochemistry
was performed on 5 -mm thick paraffin-embedded sec-
tions from SGs and from tonsils (used as positive con-
trols), as previously described [5, 7]. Isotype-matched
irrelevant antibodies were used as a negative control.
The primary antibodies anti-human mast cell tryptase
(clone AA1) (Dako, Glostrup, Denmark) (1:100 dilution),
rabbit anti-human IL-17 (Santa Cruz Biotechnology,
Dallas, TX, USA) (1:100 dilution), rabbit anti-human IL-17
(R&D Systems, Minneapolis, MN, USA) (1:100 dilution),
rabbit anti-human IL-23p19 (BioLegend, San Diego, CA,
USA) (1:50 dilution), rabbit anti-human p-STAT3 (Cell
Signaling Technology, Beverly, MA, USA) (1:50 dilution)
and mouse anti-human CD3 (Dako) (1:100 dilution) were
added and incubated for 1 h at room temperature. For
control staining, primary antibodies were replaced with
irrelevant isotype-matched antibodies (AbCam). The
slides were incubated for 30 min with peroxidase-conju-
gated Dako EnVision polymer and peroxidase activity was
visualized using diaminobenzidine chromogen (Dako).
Slides were lightly counterstained with haematoxylin
before dehydration and mounting in DePex (VWR
International, Oslo, Norway). To characterize IL-17-produ-
cing cells, double staining was performed on paraffin-
embedded sections of human SGs. Sections were incu-
bated with unlabelled rabbit anti-human IL-17 and mouse
anti-human tryptase antibodies and then treated with
FITC-conjugated anti-mouse (Alexa fluor, Invitrogen Life
Technologies, Monza, Italy) or Rhodamine Red-conju-
gated (Alexa fluor, Invitrogen) anti-rabbit antibodies plus
RNasi (200 ng/ml) and counterstained using Toto-3 iodide
(642/660; Invitrogen). Confocal analysis was used to ac-
quire fluorescence staining.
Flow cytometry
SG tissues were extensively washed in saline buffer and
enzymatic digestion was performed using collagenase
(1.5 mg/ml; Life Technologies, Carlsbad, CA, USA) in
RPMI 1640 (Invitrogen) supplemented with 10% heat-
inactivated pooled human AB-positive serum, 2 mM L-glu-
tamine, 20 mM N-(2-hydroxyethyl) piperazine-N0-(2-etha-
nesulphonic acid) (HEPES), 100 U/ml penicillin, 100 mg/ml
streptomycin and 5 105M 2-ME, for 2 h. Recovered
cells were then cultured with phorbol myristate acetate
(PMA; 50 ng/ml) and ionomycin (1 mg/ml) and incubated
at 37C in 5% CO2. After 2 h of incubation, Brefeldin A
(10 mg/ml; Sigma, St Louis, MO, USA) was added and
after 16 h of incubation cells were collected and stained
with the following mAbs: anti-human CD3-APC (BD
Biosciences, San Jose, CA, USA), anti-human tryptase-
PE (clone AA1, Dako) and anti-human IL-17- (BD
Biosciences). Isotype-matched irrelevant antibodies
were used as a negative control. Total cells were incu-
bated with mAbs for 30 min on ice and washed twice in
PBS, containing 0.1% (w/v) NaN3. After surface staining,
the cells were fixed with 1% (w/v) paraformaldehyde
(Sigma) for 30 min at 4C and then were permeabilized
with a permeabilization solution (BD Biosciences) for
10 min at room temperature and stained with antibodies
to intracellular antigens for 30 min at 4C. Four-colour flow
cytometry analysis was performed using a FACSCalibur
(BD Biosciences). At least 50 000 cells (events) were
acquired for each sample.





Age, median (range), years 44 (3572) 55 (3067) 0.68
Female, n (%) 13 (86) 10 (100) 0.77
Disease duration, median
(range), months
48 (22100) 65 (18120) 0.18
ANAs, % of patients 86 — —
Anti-Ro and/or anti-LA
antibodies, % of patients
66 — —
RF, % of patients 40 — —
ESR, mean (S.D.), mm/h 28 (11) 11 (3) <0.001
CRP, mean (S.D.), mg/l 9 (2) 4 (2) <0.05
pSS: primary SS; nSS: controls.
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Isolation of mast cells from peripheral blood
mononuclear cells and in vitro culture
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from heparinized blood samples of 10 pSS patients
and 10 nSS, as previously described [7]. CD117+ cells
were purified by positive selection using a mouse anti-
human CD117 antibody and anti-mouse IgG microbeads
(Miltenyi-Biotec, Bisley, UK) for the magnetic separation.
Next, 1 105 CD117+ cells from patients and controls,
pre-activated with N-formyl-Met-Leu-Phe (fMLP), were
cultured alone or co-cultured with heterologous CD117
cells, in triplicate, in 96-well round-bottom plates in a
volume of 200 ml/ well. After 72 h of culture the cells
were stained with the following antibodies: anti-human-
CD4-APC, anti-human-IL17-Percp (BD Biosciences) and
anti-human-CD117-PE (BD Biosciences). For in vitro cyto-
toxicity assays, cells were treated for 2 h with RTX
(10 mg/ml). Control cells received media only. After treat-
ment, 1 106 cells were plated in duplicate in a 24-well
plate in a volume of 1 ml/well and incubated at 37C in 5%
CO2 and 90% humidity for 5 days. A cytotoxicity assay
was performed using the FITC-Apoptosis detection kit
(BD Biosciences). The results were expressed as a
percentage of annexin-positive, propidium iodide
(PI)negative cells.
Statistical analysis
Statistical analysis was carried out using GraphPad Prism
software (GraphPad Software, La Jolla, CA, USA). Data




Fifteen patients (2 men and 13 women) with active pSS
were consecutively included between January 2010 and
January 2012 in the study. All the patients received four
infusions of RTX, completed the follow-up visits through
week 48 and underwent labial SG biopsy at baseline and
after 48 weeks. RTX was shown to be effective in ameli-
orating whole saliva flow rate [mean 0.22 ml/min (S.D. 0.13)
at baseline and 0.5 (S.D. 0.2) at week 48, P= 0.0002] and
the SG function assessed by Schirmer’s test [mean
5.1 mm/5 min (S.D. 2.1) at baseline and 9.3 (S.D. 2.3) at
week 48, P= 0.0001].
Mast cells and T cells produce IL-17 in the SGs
of pSS
Since anti-IL-17 antibodies from different suppliers can
give conflicting results [15], to evaluate the SG location
of IL-17-expressing cells we used two different anti-
human IL-17 antibodies. The first antibody, obtained
from Santa Cruz Biotechnology, showed a diffuse, in-
tense, cytoplasmic staining of mononuclear, epithelial
and vascular endothelial cells (Fig. 1A). In contrast, the
antibody obtained from R&D Systems predominantly
marked large cells with round-to-oval morphology scat-
tered in the periphery of lymphocytic foci and around
blood and lymphatic microvessels that highly resembled
mast cells (Fig. 1B and C; Fig. 1D shows isotype control
antibody staining). We performed additional double stain-
ing with CD3/IL-17A antibody and tryptase/IL-17A anti-
body in order to clarify the nature of the IL-17A-positive
cells, confirming that both T lymphocytes (Fig. 1EG) and
mast cells (Fig. 1HJ) express IL-17A. To confirm the cel-
lular source of IL-17 among SGs of pSS patients, SG
mononuclear cells were isolated from five pSS patients
and five controls and analysed for IL-17 production by
flow cytometry. As shown in Fig. 1L, both IL-17-producing
CD4+ T cells and mast cells were significantly increased in
the SGs of pSS patients vs controls.
RTX therapy is accompanied by reduced expression
of IL-17 in the SGs of pSS patients
We next evaluated the effect of RTX on the expression of
IL-17, IL-23p19 and p-STAT3 in pSS patients. After RTX
therapy we observed a significant depletion of CD20+ B
cells (data not shown) without a significant modulation in
the SG expression of IL-23p19 (Fig. 2AC) and of p-STAT3
(Fig. 2DF). Conversely, a significant reduction in the ex-
pression of IL-17 was clearly demonstrable (Fig. 3AC)
and was accompanied by a pronounced tissue depletion
of tryptase-positive cells (Fig. 3DF) but not in the number
of tissue-infiltrating CD3+ cells (Fig. 3GI).
RTX reduces circulating mast cells and induces
in vitro mast cell apoptotic death
Since the depletion of tissue mast cells was observed
after RTX therapy, we next evaluated the frequency of
circulating mast cells in pSS patients before and after
RTX therapy. Although the percentage of circulating
mast cells was not increased in pSS patients compared
with controls (data not shown), a significant depletion of
peripheral mast cells was observed after RTX therapy
(Fig. 4A). We next assessed whether the observed
changes in mast cell density could be attributable to a
direct cytotoxic effect of RTX therapy. PBMCs isolated
from pSS patients and controls were cultured with RTX
and the percentage of mast cells was evaluated. An im-
portant and significant increase in the percentage of
apoptotic mast cells, shown by annexin V or annexin
and PI labelling, was observed in both patients and con-
trols after incubation with RTX (Fig. 4B and C).
Mast cells isolated from pSS patients potently drive
Th17 polarization
We next analysed the capacity of mast cells isolated from
pSS patients and healthy controls to increase human Th17
cells in culture. Isolated PBMCs from patients and con-
trols were first depleted by homologous mast cells and
then incubated with heterologous activated mast cells.
As shown in Fig. 4D, mast cells isolated from pSS patients
produced a greater increase of Th17 cells than mast cells
from healthy controls (Fig. 4E), suggesting an important
role of mast cells in regulating the Th17 response in pSS
patients.
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FIG. 1 IL-17 is expressed by CD3+ T cells and mast cells in the salivary glands (SGs) of patients with primary SS (pSS)
Representative immunostaining for IL-17 in pSS patients. Different results were obtained with two different antibodies.
(A) Intense cytoplasmic staining of mononuclear, epithelial and vascular endothelial cells was observed with the Santa
Cruz antibody. (B and C) The antibody from R&D Systems predominantly marked large cells with round-to-oval
morphology scattered in the periphery of lymphocytic foci. (D) Representative paraffin sections of salivary glands of pSS
patients stained with rabbit immunoglobulins (isotype control). (EG) Representative images of confocal analysis of CD3
and IL-17 (R&D) co-localization in SG tissues of pSS patients: (E) single staining for CD3, (F) single staining for IL-17,
(G) merged double staining of CD3 (green) and IL-17 (red). (HJ) Representative images of confocal analysis of triptase
and IL-17 (Santa Cruz) co-localization in SG tissues of pSS patients: (H) single staining for triptase, (I) single staining for
IL-17, (J) merged double staining of triptase (green) and IL-17 (red). (AJ) Original magnification 250. (K) Percentage of
IL-17-expressing cells evaluated by flow cytometry among isolated SG mononuclear cells of pSS patients and controls.
Both CD4+ and mast cells isolated from pSS patients produced significantly more IL-17 than control subjects.
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This is the first study to show that RTX treatment in pSS
patients is accompanied by a large reduction of the SG
expression of IL-17, but not IL-23 and p-STAT3, suggest-
ing a specific role of RTX on IL-17-producing cells that is
not mediated by modulation of the IL-23 pathway. A sig-
nificant reduced IL-17 expression was observed in the
SGs of RTX-treated pSS patients, suggesting a direct
role of RTX in modulating SG IL-17 expression.
Although CD4+ T cells were thought to be the most im-
portant cell type involved in IL-17 responses, several stu-
dies indicate that IL-17 in humans is produced by a broad
spectrum of cells of the innate and adaptive immune sys-
tems, with different cell types producing IL-17 at different
sites and phases of tissue inflammation [16]. Conflicting
data were obtained from studies analysing the expression
of IL-17 by immunohistochemistry in inflamed human tis-
sues, with T cells and mast cells being indicated, in a
mutually exclusive manner, as the main IL-17 producer
cells [1719]. These results seem to be only apparently
conflicting, and are probably dependent more on the
type of antibody used rather than real differences in pa-
tients enrolled and/or different stages of disease [15]. To
clarify which cells produce IL-17 in the SGs of pSS pa-
tients in this study we evaluated two different antibodies
by immunohistochemistry, demonstrating that both CD3+
cells and mast cells are important cellular sources of IL-17
in the SGs of pSS patients. The production of IL-17 from
SG T lymphocytes and mast cells of pSS patients was
also confirmed by flow cytometry analysis performed on
isolated SG mononuclear cells.
FIG. 2 IL-23p19 and p-STAT3 expression is not modified by RTX therapy in the salivary glands (SGs) of patients with
primary SS (pSS)
(A and B) Representative immunostaining for IL-23p19 in pSS SGs (A) before and (B) after RTX therapy. (C) Number of
IL-23p19-positive cells in the SGs before and after RTX therapy. (D-and E) Representative immunostaining for p-STAT3 in
pSS SGs (D) before and (E) after RTX therapy. (F) Number of IL-23p19-positive cells in the SGs before and after RTX
therapy. Representative image of isotype control staining for (G) IL-23p19 and (H) p-STAT3. (A, B, D, E, G and H) Original
magnification 250.
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RTX is a chimeric mAb that induces B cell depletion and
is therefore used to treat diseases in which B cells are
overactive or dysfunctional [20]. Together with the deple-
tion of B cells, recent evidence indicates that treatment
with RTX may reduce the exaggerated Th17 response
occurring in RA synovial tissues [12] and the production
of IL-22 in the SGs of pSS patients [13], and suggests a
greater potential role of RTX in the treatment of IL-17/IL-
22-related immune diseases.
In our study, RTX treatment globally reduced the
amount of IL-17 in the SGs. But while the number of T
cells was not significantly affected, a large decrease in
tissue and circulating mast cells was observed, suggest-
ing a specific immunologic effect of RTX on the mast cell
compartment. The reduction of mast cells appears to be
specifically induced by RTX, as demonstrated by our
in vitro experiments where incubation of mast cells from
patients and controls with RTX was followed by significant
mast cell apoptosis. We actually do not know the mech-
anism of RTX-dependent apoptosis of mast cells.
However, we speculate that, because of the structural
homology of CD20 protein and the high-affinity IgE recep-
tor beta chain (FcepsilonRIbeta) [21] expressed on mast
cells, RTX may non-specifically bind to mast cells, indu-
cing their apoptotic death.
Studies in both human disease and animal models sup-
port the idea that mast cells are involved in the initiation of
inflammatory response by producing and promoting the
release of proinflammatory cytokines. In particular, mast
cells seem to be able to skew the immune reaction toward
a Th17 response through mechanisms that require IL-6
and OX40 engagement [22], IL-33/ST2 stimulation [23]
and modulation of dendritic cell maturation and function
[24]. In our in vitro studies, mast cells isolated from pSS
patients strongly induced T cells to produce IL-17, con-
firming the results of previous studies and suggesting a
potential role of mast cells in organizing the adaptive
IL-17-mediated immune responses in pSS. We obviously
cannot know if the activation of mast cells precedes the
Th17 response or vice versa. However, in view of the fact
FIG. 3 IL-17 expression is significantly reduced by RTX therapy in the salivary glands (SGs) of patients with primary SS
(pSS) and is accompanied by tissue depletion of mast cells
(A and B) Representative immunostaining for IL-17 in pSS SGs (A) before and (B) after RTX therapy. (C) Number of
IL-17-positive cells in the SGs before and after RTX therapy. (D and E) Representative immunostaining for CD3 in
pSS SGs (D) before and (E) after RTX therapy. (F) Number of CD3+ cells in the SGs before and after RTX therapy.
(G and H) Representative immunostaining for tryptase in pSS SGs (G) before and (H) after RTX therapy. (I) Number of
tryptase-positive cells in the SGs before and after RTX therapy. (A, B, D, E, G and H) Original magnification 250.
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that mast cells are resident tissue cells, one could assume
a primary role of mast cells in orchestrating the immune
Th17 response.
In conclusion, this study suggests that RTX acts on pSS
patients by globally reducing the expression of IL-17 and
specifically inducing a pronounced apoptotic depletion of
mast cells.
Rheumatology key messages
. T lymphocytes and mast cells are the main cellular
source of IL-17 in primary SS (pSS) salivary glands.
. Rituximab (RTX) acts on pSS patients by reducing
the expression of IL-17 but not IL-23p19.
. RTX depletes tissue and circulating mast cells in
pSS.
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